Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04991116 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04991116 · ClinicalTrials.gov record · last posted 2026-03-05

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

StatusActive, Not Recruiting
PhasePhase 3
Started2022-06-30
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
An open label phase 3 study

Amendment record 26 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 26 times since 2021-08-04; most recent amendment 2026-03-04. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-03-04
Status change Recruiting→Active, Not Recruitingv26
2023-11-02
Status change Active, Not Recruiting→Recruitingv11
2022-08-05
Status change Recruiting→Active, Not Recruitingv7
2022-07-08
Status change Not Yet Recruiting→Recruitingv6
Trial Details
NCT Number NCT04991116
Lead Sponsor Sun Pharmaceutical Industries Limited
Conditions Psoriatic Arthritis
Enrollment 529 participants
Start Date 2022-06-30
Primary Completion 2028-12 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-05